What is Takotsubo (stress) cardiomyopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Takotsubo Cardiomyopathy?

Takotsubo cardiomyopathy is a reversible stress-induced cardiac syndrome characterized by transient left ventricular dysfunction that mimics acute myocardial infarction but occurs in the absence of obstructive coronary artery disease. 1

Core Defining Features

The syndrome is distinguished by three essential characteristics that separate it from other cardiac conditions:

  • Reversible myocardial dysfunction is the hallmark, with the left ventricle developing acute dysfunction that completely resolves over days to weeks (typically 1-4 weeks) 1
  • Absence of obstructive coronary disease on coronary angiography, with no significant stenosis despite presentation mimicking acute coronary syndrome 1
  • Stress-triggered pathophysiology following emotional or physical stressors, precipitating a catecholamine surge that causes myocardial dysfunction 1

Clinical Presentation

Patients present identically to acute myocardial infarction, making initial differentiation impossible without imaging:

  • Acute chest pain or dyspnea as the primary symptom 2, 3
  • ST-segment elevation or T-wave inversion on ECG, most often in precordial leads 2, 4
  • Elevated cardiac troponin levels that are modest and disproportionately low relative to the extensive wall motion abnormalities seen 1, 2
  • Some patients present with hypotension or cardiogenic shock rather than chest pain 4

Characteristic Morphological Patterns

The classic appearance involves specific regional wall motion abnormalities:

  • Apical ballooning pattern (most common): left ventricular apical akinesia with basal hyperkinesis, creating the characteristic "takotsubo" (Japanese octopus trap) appearance 1, 2
  • Variant forms include mid-ventricular involvement with sparing of apex and base, basal involvement (inverse takotsubo) with apical hyperkinesis, and biventricular involvement 5, 1
  • Wall motion abnormalities typically involve all three major coronary artery territories despite absence of coronary stenosis 4

Pathophysiological Mechanism

The underlying mechanism centers on catecholamine toxicity:

  • Catecholamine surge is the primary mechanism, with supraphysiological elevations of plasma catecholamines documented during acute episodes 5
  • β2-adrenergic receptor signaling switches from Gs to Gi protein signaling with high circulating epinephrine levels, causing negative inotropy while protecting against apoptosis 5
  • Regional differences in adrenergic receptor density explain apical involvement—the ventricular apex has increased β2-adrenergic receptor density despite sparse sympathetic innervation 5
  • Contributing factors include microvascular vasospasm, impaired fatty acid metabolism, and base-to-apex perfusion gradient differences 5

Epidemiology and Risk Factors

The syndrome has a striking demographic pattern:

  • Female predominance with approximately 90% of cases occurring in women 5
  • Postmenopausal status is the strongest risk factor, with 96% of cases in women ≥50 years of age 5
  • Mean age of 66.8 years 5
  • Pre-existing psychiatric disorders (anxiety, depression) may increase susceptibility 5
  • Accounts for 2% of myocardial infarction with nonobstructive coronary arteries (MINOCA) 6

Triggering Events

Both emotional and physical stressors can precipitate the syndrome:

  • Emotional stressors: major depressive episodes, mourning, profound psychological stress 5, 7
  • Physical stressors: acute medical illness (neurological conditions, respiratory failure, sepsis), surgical procedures, chemotherapy 5
  • Endocrine disorders (thyroid dysfunction) can alter cardiovascular response to catecholamines 5

Acute Complications

Despite reversibility, serious complications occur during the acute phase:

  • Heart failure and cardiogenic shock (27% in one series) are the most serious complications and leading causes of death 7
  • Life-threatening ventricular arrhythmias due to QT-interval prolongation 6, 8
  • Left ventricular thrombus formation, particularly with severe LV dysfunction and extended apical ballooning 9
  • Transient left ventricular outflow tract obstruction 6, 5
  • Ventricular rupture (rare) 6
  • Transient right ventricular dysfunction, which is associated with more complications, longer hospitalization, and worse left ventricular systolic dysfunction 2, 4

Diagnostic Confirmation

Diagnosis requires specific criteria and complete recovery:

  • Diagnosis is made based on Mayo Clinic or InterTAK diagnostic criteria 6
  • Complete functional recovery is required to confirm the diagnosis, with left ventricular function normalizing typically within 1-4 weeks 1
  • Serial echocardiography is essential to document improvement in cardiac function 4
  • Cardiac MRI is increasingly used to differentiate from acute coronary syndrome in patients with abnormal coronary arteries 2

Prognosis

The long-term outlook is generally favorable but not without risk:

  • In-hospital mortality occurs at similar levels to acute coronary syndrome, significantly affected by underlying diseases 8
  • Most deaths occur in the first 10 days of hospitalization due to cardiogenic shock 7
  • Recurrence rate is approximately 8% 7
  • Long-term prognosis after recovery is overwhelmingly favorable with supportive therapy 3

References

Guideline

Classification and Characteristics of Takotsubo Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Takotsubo cardiomyopathy a short review.

Current cardiology reviews, 2013

Research

Takotsubo cardiomyopathy.

Journal of general internal medicine, 2008

Guideline

Causes and Mechanisms of Takotsubo Cardiomyopathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Immediate Treatment for Takotsubo Cardiomyopathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.